Ozempic and Hypertension: Clinical Evidence and Genetic Context

Last reviewed: May 24, 2026

Last updated: May 24, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Ozempic (semaglutide) has demonstrated modest reductions in blood pressure in clinical trials, though these improvements are often secondary to weight loss and improved metabolic health rather than direct antihypertensive action. Study participants using GLP-1 receptor agonists typically saw systolic blood pressure reductions of 5–10 mmHg, with greater benefits in those who experienced significant weight reduction.

For patients managing both weight and hypertension, understanding whether a GLP-1 medication might contribute to blood pressure control requires a nuanced evaluation of your metabolic profile, genetic predispositions, and overall cardiovascular health. PlexusDx's precision-wellness approach includes both compounded GLP-1 options and genetic testing to help support a more informed clinical conversation with your provider.

How GLP-1 Medications Influence Blood Pressure

GLP-1 receptor agonists lower blood pressure through several interconnected mechanisms: weight loss reduces vascular strain, improved insulin sensitivity decreases systemic inflammation, and direct effects on endothelial function may enhance blood vessel relaxation. These changes typically emerge over weeks to months as metabolic improvements accumulate.

Clinical trials consistently show that semaglutide and tirzepatide reduce systolic blood pressure by 5–10 mmHg on average. However, the magnitude of benefit varies significantly among individuals, influenced by baseline weight, renal function, existing antihypertensive regimens, and genetic factors affecting glucose and lipid metabolism.

Clinical Evidence: Blood Pressure Outcomes Across Key Trials

Major randomized controlled trials including SUSTAIN-6 (semaglutide in type 2 diabetes) and SURMOUNT-1 (tirzepatide for weight management) documented consistent but modest blood pressure reductions. These studies reveal that outcomes depend heavily on the degree of weight loss achieved and baseline metabolic status.

Trial / Population	GLP-1 Agent	Systolic BP Change	Weight Loss
SUSTAIN-6 (T2D, cardiovascular risk)	Semaglutide 1.0 mg	−3 to −4 mmHg	−3 to −6 kg
STEP 1 (Obesity, non-diabetic)	Semaglutide 2.4 mg	−5 to −6 mmHg	−10 to −15 kg
SURMOUNT-1 (Obesity)	Tirzepatide 15 mg	−6 to −8 mmHg	−20 to −25 kg
Observational data (real-world)	Compounded GLP-1s	−4 to −7 mmHg (mean)	Variable; −5 to −20 kg

Genetic Factors That May Affect Your Blood Pressure Response

Your genetic makeup influences how your body responds to GLP-1 therapy and, by extension, how much blood pressure benefit you might experience. Variants in the GLP1R gene (rs6923761), GIPR gene (rs1800437), and FTO gene (rs9939609) affect insulin secretion, appetite regulation, and metabolic capacity—all of which influence weight loss trajectory and cardiovascular outcomes.

PlexusDx's Precision Peptide Genetic Test examines predispositions in these peptide signaling pathways. This information may help provide context about your individual metabolic response potential, supporting a more targeted conversation with your provider about whether GLP-1 therapy aligns with your cardiovascular and weight management goals.

Who Should Consider GLP-1 Therapy for Blood Pressure Support and Why

GLP-1 medications are most appropriate for patients with hypertension who also have overweight or obesity, prediabetes, or type 2 diabetes. They should not replace primary antihypertensive agents but may serve as adjunctive support through weight loss and metabolic improvement. Patients on existing blood pressure medications require monitoring because weight loss can sometimes necessitate dose adjustments.

Before starting any GLP-1 therapy, discuss with your provider your current antihypertensive regimen, kidney function, history of diabetic retinopathy, and any family history of thyroid or pancreatic disease. Your provider may order baseline labs and blood pressure readings to establish whether GLP-1 therapy is appropriate and to monitor for interactions or changes in blood pressure control over time.

How PlexusDx Supports a More Personalized Approach

PlexusDx offers compounded semaglutide and tirzepatide through licensed 503A pharmacies at lower price points than branded alternatives, making precision GLP-1 therapy more accessible. Our Precision Peptide Genetic Test examines predispositions in GLP1R, GIPR, FTO, and MC4R pathways—may help provide context about your individual metabolic and cardiovascular response potential.

The Precision Peptide Genetic Test reveals your genetic predispositions in peptide signaling pathways but does not predict your exact medication response or guarantee blood pressure reduction. Instead, these insights should be interpreted with a qualified healthcare provider to understand how your genetic profile may influence weight loss capacity, metabolic flexibility, and potential cardiovascular benefits from GLP-1 therapy.

Combining genetic testing results with clinical biomarkers (fasting glucose, triglycerides, blood pressure readings, and renal function) creates a more complete picture for your provider. This personalized framework can support a more informed decision about whether compounded GLP-1 therapy is appropriate for your hypertension and metabolic health goals.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Which trial row in the article's blood pressure table shows the largest systolic drop?

The SURMOUNT-1 row, where tirzepatide 15 mg in an obesity population was paired with a systolic change of minus 6 to minus 8 mmHg alongside 20 to 25 kg of weight loss. The article's SUSTAIN-6 row is the smallest at minus 3 to minus 4 mmHg, and STEP 1 sits between them. The pattern the post draws from this is that blood pressure change tracked with how much weight was lost.

Does the article suggest a GLP-1 can replace a primary antihypertensive agent?

No. The post states plainly that these medications should not replace primary antihypertensive agents, and describes them instead as possible adjunctive support working through weight loss and metabolic improvement. It also notes that patients already on blood pressure medication require monitoring, because weight loss can sometimes make adjustments necessary. Any change to an existing regimen is a decision for your prescriber.

Why does the post describe the blood pressure benefit as secondary rather than a direct antihypertensive effect?

Because the article attributes most of the improvement to weight loss and better metabolic health rather than to direct action on blood pressure. It lists three interconnected routes: weight loss reducing vascular strain, improved insulin sensitivity lowering systemic inflammation, and possible direct effects on endothelial function that help blood vessels relax. The post says these changes typically emerge over weeks to months.

What does the article say a provider should review before starting GLP-1 therapy in someone with hypertension?

The post lists your current antihypertensive regimen, kidney function, any history of diabetic retinopathy, and family history of thyroid or pancreatic disease as the items to raise. It adds that your provider may order baseline labs and blood pressure readings, both to judge whether GLP-1 therapy is appropriate and to watch for interactions or shifts in blood pressure control over time.

Who does the post identify as the most appropriate candidates for GLP-1 support alongside hypertension?

The article says these medications are most appropriate for patients who have hypertension together with overweight or obesity, prediabetes, or type 2 diabetes. It frames the blood pressure effect as adjunctive rather than primary. It also cautions that the size of any benefit varies with baseline weight, renal function, and the antihypertensive regimen already in place, so candidacy remains a clinical judgment.

Related Reading

• Ozempic For Hypertension
• What Are Spleen Disease Symptoms Risk Factors And Genetic Testing Benefits
• Lifemd Ozempic
• Eden Ozempic

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.